Enliven therapeutics announces $90 million private placement financing and provides pipeline updates

Financing includes participation from new and existing investors net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026 and through multiple key clinical milestones for elvn-001 and elvn-002 company to host an event with kols on april 11, 2024, to discuss initial proof of concept data from a phase 1a trial evaluating elvn-001 in adults with chronic myeloid leukemia (cml) boulder, colo., march 19, 2024 (globe newswire) -- enliven therapeutics, inc. (enliven or the company) (nasdaq: elvn), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that it has entered into a securities purchase agreement for a private investment in public equity (pipe) financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses.
ELVN Ratings Summary
ELVN Quant Ranking